• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0
×

Target

Host

Species Reactivity

Species Reactivity

Conjugate

Conjugate

LYPLA3 Polyclonal antibody

LYPLA3 Polyclonal Antibody for WB, IHC, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse

Applications

WB, IHC, IF, ELISA

Conjugate

Unconjugated

Cat no : 10863-2-AP

Synonyms

1 O acylceramide synthase, ACS, Group XV phospholipase A2, GXVPLA2, LCAT like lysophospholipase, LLPL, LPLA2, LYPLA3, Lysophospholipase 3, Lysosomal phospholipase A2, phospholipase A2, group XV, PLA2G15

Validation Data Gallery

Filter:
  • Western Blot (WB) analysis of mouse spleen tissue using LYPLA3 Polyclonal antibody (10863-2-AP)

    WB analysis of mouse spleen using 10863-2-AP

    mouse spleen tissue were subjected to SDS PAGE followed by western blot with 10863-2-AP (LYPLA3 antibody at dilution of 1:1000 incubated at room temperature for 1.5 hours.

  • Western Blot (WB) analysis of mouse kidney tissue using LYPLA3 Polyclonal antibody (10863-2-AP)

    WB analysis of mouse kidney using 10863-2-AP

    mouse kidney tissue were subjected to SDS PAGE followed by western blot with 10863-2-AP (LYPLA3 antibody at dilution of 1:1000 incubated at room temperature for 1.5 hours.

  • Immunohistochemistry (IHC) staining of human liver cancer tissue using LYPLA3 Polyclonal antibody (10863-2-AP)

    IHC staining of human liver cancer using 10863-2-AP

    Immunohistochemical analysis of paraffin-embedded human liver cancer tissue slide using 10863-2-AP (LYPLA3 antibody) at dilution of 1:200 (under 40x lens)..

  • Immunohistochemistry (IHC) staining of human liver cancer tissue using LYPLA3 Polyclonal antibody (10863-2-AP)

    IHC staining of human liver cancer using 10863-2-AP

    Immunohistochemical analysis of paraffin-embedded human liver cancer tissue slide using 10863-2-AP (LYPLA3 antibody) at dilution of 1:200 (under 10x lens)..

☆対象製品が30%オフ！組換えタンパク質&免染用試薬 >>> キャンペーン実施中！

Tested Applications

Positive WB detected inmouse spleen tissue, mouse kidney tissue
Positive IHC detected inhuman liver cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:500-1:2000
Immunohistochemistry (IHC)IHC : 1:50-1:500
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Published Applications

IFSee 1 publications below

Product Information

10863-2-AP targets LYPLA3 in WB, IHC, IF, ELISA applications and shows reactivity with human, mouse samples.

Tested Reactivity human, mouse
Cited Reactivityhuman
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen LYPLA3 fusion protein Ag1304 相同性解析による交差性が予測される生物種
Full Name phospholipase A2, group XV
Calculated molecular weight 47 kDa
Observed molecular weight 42-57 kDa
GenBank accession numberBC011640
Gene symbol PLA2G15
Gene ID (NCBI) 23659
RRIDAB_2283832
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

PLA2G15 is also named as LYPLA3 and belongs to the AB hydrolase superfamily. It has transacylase and calcium-independent phospholipase A2 activity. PLA2G15 catalyzes the formation of 1-O-acyl-N-acetylsphingosine and the concomitant release of a lyso-phospholipid. It can be detected as 42-47 kDa and 57 kDa due to the N-glycosylated modification (PMID:11790796).

Protocols

Product Specific Protocols
WB protocol for LYPLA3 antibody 10863-2-APDownload protocol
IHC protocol for LYPLA3 antibody 10863-2-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanIF

bioRxiv

Loss of the lysosomal protein CLN3 modifies the lipid content of the nuclear envelope leading to DNA damage and activation of YAP1 pro-apoptotic signaling

Authors - Neuza Domingues
View Article